With the presented computer‐aided approach coupled with a stepwise experimental validation, we have reported here the design of a novel chemical series binding to KRASG12C with high potential for the development of pioneering KRAS‐targeted anti‐cancer treatments. The gene discussed is KRAS; the disease is cancer.